Additional file 2 of Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial

Additional file 2: Table S1. MSC quality control metrics for single infusion for N = 15 subjects. MSCs are expected to be positive for CD73 and CD29 and negative for CD45 and CD31. Columns 3–7 in the table indicate the percent of cells expressing the marker. Table S2. Individual subject level summary of disease & treatment history and efficacy outcomes. Both medications taken at the start of the trial and previously failed medications are described. Only medications with the capacity to alter the disease process transiently or permanently are reported (DMARDs or Glucocorticoids). Individual subject comparisons (baseline vs week 52) of Tender joint count, swollen joint count and C-reactive protein (CRP) that showed significant changes during the trial, are reported as indicators of disease activity. Table S3. Summary statistics of all safety measures. Summary evaluation of lab values at the baseline and each of the follow-up visits. Overall significance values are displayed *p < 0.05; Mixed Effect Analysis corrected with the Geisser-Greenhouse correction followed by Dunnett’s test for multiple comparisons. Table S4. Summary statistics of all efficacy measures. Summary evaluation of joint count data and inflammatory parameters at the baseline and each of the follow-up visits. ES are reported for statistically significant values (bold). *p < 0.01 and **p < 0.001 (Holm–Šídák correction for multiple comparisons); Wilcoxon-signed rank test.